Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Depreciation & Amortization (CF) (2016 - 2017)

Tenax Therapeutics' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $3022.0 for Q4 2017.

  • For Q4 2017, Depreciation & Amortization (CF) fell 31.64% year-over-year to $3022.0; the TTM value through Dec 2017 reached $13621.0, down 28.13%, while the annual FY2023 figure was $8000.0, 55.55% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2017 was $3022.0 at Tenax Therapeutics, down from $3143.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.3 million in Q1 2014 and bottomed at $3022.0 in Q4 2017.
  • The 5-year median for Depreciation & Amortization (CF) is $17475.0 (2014), against an average of $392216.9.
  • The largest YoY upside for Depreciation & Amortization (CF) was 60.37% in 2015 against a maximum downside of 98.46% in 2015.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.3 million in 2013, then plummeted by 98.35% to $37893.0 in 2014, then tumbled by 66.62% to $12650.0 in 2015, then tumbled by 65.05% to $4421.0 in 2016, then tumbled by 31.64% to $3022.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Depreciation & Amortization (CF) are $3022.0 (Q4 2017), $3143.0 (Q3 2017), and $3424.0 (Q2 2017).